摘要
目的观察全身化疗联用腹腔内化疗对II^III期胃癌患者的疗效是否优于单用全身化疗。方法2000年1月至12月,58例II^III期胃癌根治术后患者被随机分到不同治疗组(全身化疗联用腹腔内化疗作为研究组,单用全身化疗为对照组),并作随访观察。结果三年以后,研究组的复发率(17.2%)低于对照组(44.4%),而研究组的生存率(86.2%)明显高于对照组(59.3%),两组在复发率和生存率上均有明显的统计学差异(P<0.05),而两组的毒副反应无明显的统计学差异(P>0.05)。结论全身化疗联用腹腔内化疗对II^III期胃癌根治性术后患者的疗效优于单用全身化疗,而毒副反应并无明显增加。
Objective To observe whether the efficacy of systemic venous chemotherapy plus intraperitoneal chemotherapy for patients with phase Ⅱ～Ⅲ gastric carcinoma was better than that of venous chemotherapy alone. Methods From January to December 2000, 58 patients with phase Ⅱ～Ⅲ gastric carcinoma after radical treatment were selected and treated by radical surgery, and divided randomly into two groups with different treatments （the systemic venous chemotherapy plus chemotherapy in the abdominal cavity was given to the treatment group, and venous chemotherapy alone to the control group）, conducting follow-up survey. Results With the comparison of the recurrence rate of the two groups in three years, in the treatment group, the recurrence rate （17.2%） was lower than that of the control group （44.4%）, and the survival rate （86.2%） was higher than that of the control group （59.3%）. There were statistical differences between the two groups for both rates （P〈 0.05）, and the toxicity and side effects of the two groups had no prominent differences （P〉0.05）. Conclusion The efficacy of systemic venous chemotherapy plus intraperitoneal chemotherapy for patients with phase Ⅱ～Ⅲ gastric carcinoma after radical treatment was better than that of venous chemotherapy alone. The toxicity and side effects of systemic venous chemotherapy plus intraperitoneal chemotherapy group were not apparently higher than those of the venous chemotherapy group.
出处
《现代肿瘤医学》
CAS
2005年第6期791-794,共4页
Journal of Modern Oncology
关键词
腹腔内化疗
胃癌
疗效
intraperitoneal chemotherapy
gastric carcinoma
efficacy
